Vicki L. Sato Sells 3,080 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now owns 107,976 shares in the company, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Denali Therapeutics Stock Up 2.0 %

DNLI opened at $21.26 on Friday. The firm has a market cap of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The business has a fifty day simple moving average of $24.62 and a 200-day simple moving average of $24.88.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business posted ($0.72) EPS. Sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. MONECO Advisors LLC raised its position in Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock valued at $265,000 after purchasing an additional 400 shares in the last quarter. Assetmark Inc. increased its stake in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after buying an additional 580 shares during the period. CWM LLC raised its holdings in Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after acquiring an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after acquiring an additional 920 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Denali Therapeutics by 5.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock worth $613,000 after acquiring an additional 1,372 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DNLI has been the topic of a number of research reports. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. William Blair began coverage on shares of Denali Therapeutics in a research report on Friday. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.40.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.